Inhibition of intrahepatic hepatitis B virus replication by antiviral drugs in a novel transgenic mouse model.
Transgenic mice which carry the integrated human hepatitis B virus (HBV) genome and produce HBV particles in the liver were treated with antiviral compounds, and the amount of viral DNA in the liver and serum was monitored by Southern analyses. Mouse alpha interferon (200,000 U per injection, twice daily for 3 days) and a novel nucleoside, oxetanocin G (15 mg/kg of body weight per injection, twice daily for 7 days), inhibited viral DNA synthesis in the liver almost completely. This animal model should prove useful in evaluating anti-HBV agents.
Nagahata
T
T
Institute for Molecular and Cellular Biology, Osaka University, Japan.
Araki
K
K
Yamamura
K
K
Matsubara
K
K
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D015139:Blotting, Southern; D004279:DNA, Viral / Q000032:analysis; D006147:Guanine / Q000031:analogs & derivatives / Q000494:pharmacology; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006515:Hepatitis B virus / Q000187:drug effects*; D016898:Interferon-alpha / Q000494:pharmacology; D007668:Kidney / Q000382:microbiology; D008099:Liver / Q000187:drug effects / Q000382:microbiology*; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D014740:Vidarabine / Q000494:pharmacology; D014779:Virus Replication / Q000187:drug effects*
D000998:Antiviral Agents; D004279:DNA, Viral; D006514:Hepatitis B Surface Antigens; D016898:Interferon-alpha; C057479:oxetanocin G; D006147:Guanine; D014740:Vidarabine